Summary
Teicoplanin is a recently introduced glycopeptide antibiotic for the treatment of a variety of aerobic and anaerobic Gram-positive infections. It is a mixture of 5 closely related components, of similar polarity and biological activity, and 1 or more polar hydrolysis products. Teicoplanin is rapidly and extensively absorbed from muscle and the peritoneal cavity but very poorly absorbed from the gastrointestinal tract. Following intravenous administration, the disposition kinetics are best described by a tri-exponential equation, and the majority of drug is excreted unchanged, by glomerular filtration. In patients with normal renal function, the half-lives of the first, second and terminal phases are 35 minutes, 10 hours and 87 hours, respectively. The initial volume of distribution is 0.089 L/kg, the volume of distribution at steady-state is 0.86 L/kg, clearance is 0.0114 L/h/kg and renal clearance is 0.0083 L/h/kg. Teicoplanin is highly bound in plasma to albumin (fraction unbound = 0.1) and in tissues. The pharmacokinetics are linear over a wide dose range (2 to 26 mg/kg). The minor differences in the pharmacokinetics of the components of teicoplanin can be accounted for by differences in lipophilicity. The events following multiple dosing are predicted from single dose data; renal clearance decreases in patients with renal insufficiency in a predictable manner. Negligible drug is lost during haemodialysis. As expected, clearance per kilogram is higher in children than in adults, and lower in the elderly, associated with a decrease in glomerular filtration rate with advancing years.
Tissue distribution data are limited. Concentrations, relative to those in plasma, are high in lung and bone tissue and low in fat. Animal data show high concentrations in most tissues, and particularly high in liver and kidneys. Teicoplanin penetrates slowly and poorly into cerebrospinal fluid, but relatively rapidly and effectively in synovial and pleural fluids and in soft tissue.
The manufacturer’s recommended intravenous or intramuscular dosage regimens rapidly achieve and maintain adequate plasma concentrations of teicoplanin; the dosing interval is usually 1 day. The maintenance dosing rate, but not the loading dose (if needed), must be reduced in patients with poor renal function and in the elderly. For those patients on continuous ambulatory peritoneal dialysis, the peritoneal cavity offers a convenient alternative route of drug administration.
Similar content being viewed by others
References
Ahmad R. Raichura N, Kilbane V. Whitfield E. Vancomycin: a reappraisal. (Letter) British Medical Journal 284: 1953–1954. 1982
Antrum RM. Barlow I, Ramsden C. Kester RC. A study of the concentrations of teicoplanin achieved in serum, bile and gall bladder. 8th International Symposium on Future Trends in Chemotherapy. Tirrenia. 28–30 March (Abstract), p. 49. Litografia Tacchi. Pisa. 1988
Assandri A. Bernareggi A. Binding of teicoplanin to human serum albumin. European Journal of Clinical Pharmacology 33: 191–195, 1987
Barna JCJ. Williams DH, Stone DJM. Leung TWC, Doddrell DM. Structure elucidation of the teicoplanin antibiotics. Journal of the American Chemical Society 106: 4895–4902, 1984
Bernareggi A. Cavenaghi L. Assandri A. Pharmacokinetics of (14C) teicoplanin in male rats after single intravenous dose. Antimicrobial Agents and Chemotherapy 30: 733–738. 1986
Bernareggi A, Danese A. Cometti A. Buniva G. Rowland M. Pharmacokinetics of individual components of teicoplanin in man Journal of Pharmacokinetics and Biopharmaceutics, in press. 1990
Bibler MR. Frame PT. Hagler DN. Bode RB. Staneck JH. et al. Clinical evaluation of efficacy, pharmacokinetics, and safety of teicoplanin for serious gram-positive infections. Antimicrobial Agents and Chemotherapy 31: 207–212. 1987
Bonati M. Traina GL. Gentile MG. Fellin G. Rosina R. et al. Pharmacokinetics of intraperitoneal teicoplanin in patients with chronic renal failure on continuous ambulatory peritoneal di-alvsis. British Journal of Clinical Pharmacologv 25: 761–765. 1988a
Bonati M. Traina GL. Rosina R. Buniva G. Pharmacokinetics of a single intravenous dose of teicoplanin in subjects with various degrees of renal impairment. Journal of Antimicrobial Chemotherapy 21 (Suppl. A): 29–37, 1988b
Bonati M. Traina GL, Villa G, Salvadeo A, Gentile MG, et al. Teicoplanin pharmacokinetics in patients with chronic renal failure. Clinical Pharmacokinetics 12: 292–301, 1987
Borghi A, Coronelli C Faniuolo L, Allievi G, Pallanza R, et al. Teichomycins, new antibiotics from Actinoplanes teichomy-ceticus nov. sp. IV. Separation and characterization of the components of teichomycin (teicoplanin). Journal of Antibiotics (Tokyo) 37: 615–620. 1984
Brouard RJ. Kapusnik JE. Gambertoglio JG. Schoenfeld PY, Sachdeva M, Freel K, Tozer TN. Teicoplanin pharmacokinetics and bioavailability during peritoneal dialysis. Clinical Pharmacology and Therapy 45: 674–681, 1989
Brumfitt W. Baillod R, Smith GW, Grady D. Hamilton-Miller JMT, et al. Teicoplanin for patients undergoing dialysis: microbiological and pharmacokinetic aspects. In Gialdroni-Grassi et al. (Eds) Proceedings of a workshop held at the 14th International Congress of Chemotherapy. Kyoto. 1985. pp. 23–25, University of Tokyo Press, Tokyo. 1985
Buniva G, Cavenaghi L. Pharmacokinetics of teicoplanin after repeated i.m. injections. In Ishigami (Ed.) Recent advances in chemotherapy. Antimicrobial section 3. pp. 1897–1898. University of Tokyo Press, Tokyo, 1985
Buniva G. Cavenaghi L, Frigo GM, Rosina R, Lewis P. Microbiological activity of teicoplanin in feces following oral administration. Comparison with vancomycin. 7th International Symposium on Future Trends in Chemotherapy. Tirrenia, 26–28 May (Abstract), p. 172. 1986
Buniva G, Cavenaghi L, Taglietti M, Frigo GM Pharmacokinetics of teicoplanin after single and repeated i.v. injections. Proceedings of the International Symposium on the Control of Hospital Infections. Rome. 27–29 April 1987. pp. 192–194. Edizioni Reviste Scientifiche. Firenze. 1988
Buniva G, Del Favero A, Bernareggi A. Patoia L. Palumbo R. Pharmacokinetics of 14C-teicoplanin in healthy volunteers. Journal of Antimicrobial Chemotherapy 21 (Suppl. A): 23–28, 1988
Carver PL. Nightingale CH. Quintiliani R. Sweeney K. Stevens RC. el al. Pharmacokinetics of single- and multi-dose teicoplanin in healthy volunteers. Antimicrobial Agents and Chemotherapy 33: 82–86. 1989
Cavenaghi L. Corti A. Cassani G. Comparison of the solid phase enzyme receptor assay (SPER A) and the microbiological assay for leicoplanin. Journal of Hospital Infection 7 (Suppl. A): 85–89. 1986
Coronelli C, Gallo GG, Cavalleri B. Teicoplanin: chemical, physico-chemical and biological aspects. Farmaco (Edizione Scien-tifica) 42: 767–786. 1987
Corti A. Cavenaghi L, Giani E. Cassani G. A receptor-antibody sandwich assay for teicoplanin. Clinical Chemistry 33: 1615–1618. 1987
Del Favero A, Patoia L. Rosina R. Danesc A. Bernareggi A. et al. Pharmacokinetics and tolerability of leicoplanin (T) after single increasing doses in healthy volunteers. (Abstract) Submitted to the 29th ICAAC. Houston. Texas. 17–20 September. 1989
Derbyshire N. Webb DB, Roberts D. Glew D. Williams JD. Pharmacokinetics of teicoplanin in subjects with varying degrees of renal function. Journal of Antimicrobial Chemotherapy 23: 869–876. 1989
Domart Y, Pierre C, Clair B, Garaud JJ. Regnier B. et al. Pharmacokinetics of teicoplanin in critically ill patients with various degrees of renal impairment. Antimicrobial Agents and Chemotherapy 31: 1600–1604. 1987
Editorial. Teicoplanin FPIA. Innotron Brochure, pp. 1–20, American Bioclinical, Portland. Oregon. 1989
Falcoz C, Ferry N. Pozet N. Cuisinaud G. Zech PY. et al. Pharmacokinetics of teicoplanin in renal failure. Antimicrobial Agents and Chemotherapy 31: 1255–1262. 1987
Greenwood D. Microbiological properties of teicoplanin. Journal of Antimicrobial Chemotherapy 21 (Suppl. A): 1–13, 1988
Guay DRP, Awni WM, Fant B. Kenny M. Matzke GR. Pharmacokinetics of teicoplanin in continuous ambulatory peritoneal dialysis. 28th Intersciencc Conference on Antimicrobial Agents and Chemotherapy, Los Angeles. 23–26 October 1988 (Abstract), p. 134. ASM. Washington. 1988
Jacobs F. Rocmans P. Motte S, Serruys E, Herschuelz A, et al. Penetration and bactericidal activity of teichoplanin in post-thoracotomy pleural fluids. 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 28 September-1 October 1986. (Abstract) p. 323, ASM, Washington. 1986
Janknegt R, Koelman HH, Nube MJ. Pharmacokinetics of rif-ampicin and teicoplanin during CAPD. Medical Science Research 15: 171–172, 1987
Jehl F. Monteil H. Tarral A. HPLC quantitation of the six main components of teicoplanin in biological fluids. Journal of Antimicrobial Chemotherapy 21 (Suppl. A): 53–59. 1988
Joos B, Lüthy R. Determination of teicoplanin concentrations in serum by high-pressure liquid chromatography. Antimicrobial Agents and Chemotherapy 31: 1222–1224. 1987
Joos B, Lüthy R. Identification of fluorescent glycopeptide derivatives by two consecutive high pressure liquid chromatographic procedures. Journal of Antibiotics (Tokyo) 41: 302–307, 1988
Kester RC, Barlow I, Ramsden C, Antrum RM. A study of teicoplanin accumulation in ischaemic tissues. 8th International Symposium on Future Trends in Chemotherapy. Tirrenia. 28-30 March 1988 (Abstract), p. 50. Litografia Tacchi, Pisa. 1988
Lagast H. Dodion P. Klastersky J. Comparison of pharmacokinetics and bactericidal activity of teicoplanin and vancomycin. Journal of Antimicrobial Chemotherapy 18: 513–520, 1986
Lemerle S, De La Roque F, Lamy R, Fremaux A. Bernaudin F. et al. Teicoplanin in combination therapy for febrile episodes in neutropenic and non-neutropenic paediatric patients. Journal of Antimicrobial Chemotherapy 21 (Suppl. A): 113–116. 1988
Levy J, Truong BL. Goignau H. Van Laethem Y. Butzler JP, et al. High pressure liquid chromatographic quantitation of teicoplanin in human serum. Journal of Antimicrobial Chemotherapy 19: 533–539, 1987
Lewis P. Garaud JJ, Parenti F. A multicentre open clinical trial of teicoplanin in infections caused by gram-positive bacteria. Journal of Antimicrobial Chemotherapy 21 (Suppl. A): 61–67. 1988
Malabarba A, Strazzolini P. Depaoli A. Landi M. Berti M. et al. Teicoplanin, antibiotics from actinoplanes teichomycefius Nov. S.P. VI. Chemical degradation: physicochemical and biological properties of acid hydrolysis products. Journal of Antibiotics 37: 988–999. 1984
Maserati R. Cruciani M. Azzimi M. Carnevale C, Suter F. et al. Teicoplanin in the therapy of staphylococcal neuroshunt infections. International Journal of Clinical Pharmacology Research 7: 207–213. 1987
Maskell JP. Carter JLB. Boyd RB. Williams RJ. Teicoplanin as a prophylactic antibiotic for dental bacteraemia. Journal of Antimicrobial Chemotherapy 17: 651–659. 1986
Matzke GR. Vancomycin. In Evans & Jusko (Eds) Applied pharmacokinetics: principle of therapeutic drug monitoring. 2nd ed., pp. 399–436. Applied Therapeutics, Spokane, 1986
Matzke GR. Zhanel GG. Guay DRP. Clinical pharmacokinetics of vancomycin. Clinical Pharmacokinetics 11: 257–282. 1986
McNulty CAM. Garden GMF, Wise R. Andrews JM. The pharmacokinetics and tissue penetration of teicoplanin. Journal of Antimicrobial Chemotherapy 16: 743–749. 1985
Mini E. Reali EF, Silvestri V. Montesi G, Novelli A. et al. Pharmacokinetics of leicoplanin during cardiopulmonary bypass surgery. 8th International Symposium on Future Trends in Chemotherapy, Tirrenia, 28–30 March 1988 (Abstract) p. 201. Litografia Tacchi, Pisa, 1988
Novelli A, Mazzei T, Reali EF. Mini E. Periti P. Clinical pharmacokinetics and tissue penetration of teicoplanin. International Journal of Clinical Pharmacology Research 9: 233–237. 1989.
Die S, Tozer TN. Effect of altered plasma protein binding on apparent volume of distribution. Journal of Pharmaceutical Sciences 68: 1203–1205, 1979
Parenti F. Structure and mechanism of action of leicoplanin. Journal of Hospital Infection 7 (Suppl. A): 79–83, 1986
Parenti F, Beretta G. Berti M, Arioli V. Teichomycins, new antibiotics from actinoplanes teichomyceticus nov. sp. I. Description of the producer strain, fermentation studies and biological properties. Journal of Antibiotics (Tokyo) 31: 276–283, 1978
Parrinello AE, Zecchinato F. Marini F. Musola R. Therapeutic activity of teicoplanin in gram-positive infections. In Berkarda & Kuemmerle (Eds) Proceedings of the 15th International Congress of Chemotherapy, pp. 572–574. Ecomed, Landsberg, 1987
Patton KR, Beg A. Felmingham D, Ridgway GL, Grüneberg RN. Determination of teicoplanin in serum using a bioassay technique. Drugs under Experimental and Clinical Research 13: 547–550. 1987
Reynolds PE. Inhibitors of bacterial cell wall synthesis. In Greenwood & O’Grady (Eds) The scientific basis of antimicrobial chemotherapy, pp. 13–40. Cambridge University Press, Cambridge. 1986
Rio Y, Giorgi C, Schockmel G. Didion J. Jurin F. et al. Traitement des septicémies et infections cutanées chez le brûlé par la téicoplanine. étude de sa diffusion cutanée. Pathologie et Biologie (Paris) 35: 603–607. 1987
Ripa S, Ferrante L, Mignini F. Falcioni E. Pharmacokinetics of teicoplanin. Chemotherapy 34: 178–184. 1988
Riva E, Ferry N, Cometti A, Cuisinaud G, Gallo GG, et al. Determination of teicoplanin in human plasma and urine by affinity and re versed-phase high-performance liquid chromatography. Journal of Chromatography 421: 99–110. 1987
Rosina R, Villa G, Danese A, Cavenaghi L, Picardi L. et al. Pharmacokinetics of teicoplanin in the elderly. Journal of Antimicrobial Chemotherapy 21 (Suppl. A): 39–45. 1988
Rowland M. Tozer TN. Clinical pharmacokinetics: concepts and applications, 2nd ed., Lea & Febiger, Philadelphia, 1989
Shaison G. Levergcr G. Ariel G. Pecking M. Garaud JJ. A once a day antimicrobial therapy, teicoplanin and ceftriaxone in the treatment of febrile neutropenic children with acute leukaemia. 28th Interscience Conference on Antimicrobial Agents and Chemotherapy. Los Angeles. 23–26 Oct 1988 (Abstract), p.114. ASM. Washington. 1988
Somma S. Gastaldo L. Corti A. Teicoplanin, a new antibiotic from actinoplanes leichomyceticus nov. sp. Antimicrobial Agents and Chemotherapy 26: 917–923. 1984
Stahl JP. Croize J. Wolff M. Garaud JJ. Leclercq P. et al. Poor penetration of teicoplanin into cerebrospinal fluid in patients with bacterial meningitis. (Letter) Journal of Antimicrobial Chemotherapy 20: 141–142. 1987
Tarral E. Jehl F. Tarral A. Simeoni U. Monteil H, et al. Pharmacokinetics of teicoplanin in children. Journal of Antimicrobial Chemotherapy 21 (Suppl. A): 47–51. 1988
Terragna A. Ferrea G. Loy A. Danese A. Bernareggi A. et al. Pharmacokinetics of teicoplanin in pediatric patients. Antimicrobial Agents and Chemotherapy 32: 1223–1226. 1988
Traina GL. Bonati M. Pharmacokinetics of teicoplanin in man after intravenous administration. Journal of Pharmacokinetics and Biopharmaceutics 12: 119–128. 1984
Traina GL. Gentile MG. Fellin G, Rosina R. Cavenaghi L. et al. Pharmacokinetics of teicoplanin in patients on continuous ambulatory peritoneal dialysis. European Journal of Clinical Pharmacology 31: 501–504. 1986
Venditti M. Micozzi A. Serra P. Buniva G. Palma L. et al. Intraventricular administration of teicoplanin in shunt associated ventriculitis caused by methicillin resistant staphylococcus aureus. (Letter) Journal of Antimicrobial Chemotherapy 21: 513–515. 1988
Verbist L. Teicoplanin pharmacokinetics: multiple dose study. In Gialdroni-Grassi et al. (Eds) Proceedings of a workshop held at the 14th International Congress of Chemotherapy, Kyoto, 1985, pp. 15–19. University of Tokyo Press, Tokyo. 1985
Verbist L, Tjandramaga B, Hendrickx B. Van Hecken A, Van Melle P. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrobial Agents and Chemotherapy 26: 881–886. 1984
Weil Jr. WB. The evaluation of renal function in infancy and childhood. American Journal of the Medical Sciences 229: 678–694. 1955
Williams AH, Grüneberg RN. Teicoplanin (Editorial). Journal of Antimicrobial Chemotherapy 14: 441–445. 1984
Wilson APR. Shankar S. Felmingham D. Treasure T. Gruneberg RN. Serum and tissue levels of teicoplanin during cardiac surgery: the effect of a high dose regimen. Journal of Antimicrobial Chemotherapy 23: 613–617. 1989
Wilson APR. Taylor B. Treasure T, Grüneberg RN. Patton K, et al. Antibiotic prophylaxis in cardiac surgery: serum and tissue levels of teicoplanin, flucloxacillin and tobramycin. Journal of Antimicrobial Chemotherapy 21: 201–212. 1988
Wise R. Donovan IA. McNulty CAM, Waldron R, Andrews JM. Teicoplanin, its pharmacokinetics, blister and peritoneal fluid penetration. Journal of Hospital Infection 7 (Suppl. A): 47–55. 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rowland, M. Clinical Pharmacokinetics of Teicoplanin. Clin Pharmacokinet 18, 184–209 (1990). https://doi.org/10.2165/00003088-199018030-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199018030-00002